<DOC>
	<DOCNO>NCT00243100</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat gemcitabine treat patient metastatic unresectable solid tumor . Drugs use chemotherapy , vorinostat gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Vorinostat may also stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>Vorinostat Gemcitabine Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine dose-limiting toxicity , maximum tolerate dose , pharmacokinetics vorinostat ( SAHA ) gemcitabine patient metastatic unresectable epithelial solid tumor . SECONDARY OBJECTIVES : II . Determine tumor activity regimen patient . OUTLINE : This dose-escalation , open-label study . Patients receive oral vorinostat ( SAHA ) daily day 1-14 gemcitabine IV 1-2 hour day 3 10 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SAHA gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A minimum 6 patient treated MTD . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>ECOG 02 OR Karnofsky 60100 % AST ALT = &lt; 2.5 time ULN Bilirubin = &lt; 1.5 time upper limit normal ( ULN ) Platelet count &gt; = 100,000/mm3 Absolute neutrophil count &gt; = 1,500/mm3 Creatinine normal OR creatinine clearance â‰¥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Any number type prior chemotherapy allow include prior use gemcitabine chemotherapy . A washout phase least 2 week since use prior chemotherapy radiation therapy , 6 week last regimen include nitrosoureas mitomycin C , require . Patients must histologically confirm epithelial malignancy metastatic unresectable standard curative palliative measure exist longer effective . Ability understand willingness sign write informed consent document . Patients must least one measurable lesion per RECIST Criteria accurately measure least one dimension , minimum lesion size equal twice slice thickness image study use . No symptomatic congestive heart failure No cardiac arrhythmia No ongoing active infection No psychiatric illness social situation would preclude study compliance No history allergy , significant side effect , poor tolerance gemcitabine No history allergic reaction attribute compound similar chemical biological composition vorinostat ( SAHA ) At least 2 week since prior radiotherapy Recovered prior therapy No concurrent combination antiretroviral therapy HIVpositive patient No uncontrolled illness More 2 week since prior valproic acid No concurrent investigational drug No concurrent anticancer therapy Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>